CVS Health is experiencing margin recovery in its insurance and retail pharmacy segments, signaling a successful turnaround driven by disciplined management and improved retail affordability. The company's plan to separate its retail pharmacy may cause short-term costs but could unlock value by allowing more competitive freedom and addressing regulatory challenges. Despite recent stock price dips, CVS trades at attractive valuations with potential upside over 30% to a long-term price target of $110.20. Risks include uneven margin recovery, competitive pressures, and political uncertainties.
CVS Health's turnaround story continues as the company navigates its retail pharmacy separation plans. On Pluang, CVS shares are trading at USD 82.28, up 2.90% as of Nov 05, 2026 21:31 WIB, showing positive momentum. The stock remains well below its 52-week high of USD 110.60, with a dividend yield of 3.33% and a market cap of $102.31 billion, while Pluang investors hold the stock for an average of 80 days.
CVS announced it will split into two separate public companies by mid-2028: one focusing on healthcare solutions and the other on retail pharmacy. This move caused CVS shares to drop over 11% despite strong earnings. The split will affect healthcare ...
CVS Health announced plans to split into two publicly traded companies by 2028. One company will combine Aetna, its health insurance arm, with the pharmacy benefits business, while the other will focus on operating CVS Pharmacy's retail stores and ph...
CVS Health is reportedly considering splitting into two publicly traded companies, separating its retail drugstores from its insurance and pharmacy benefit management units, including Aetna and Caremark. This move could reverse the 2018 Aetna acquisi...
CVS Health announced plans to split into two separate public companies by mid-2028, undoing its $78 billion acquisition of insurer Aetna and breaking up its integrated healthcare business. The split will separate CVS's 9,000 retail pharmacies from it...
CVS Health announced plans to separate into two independent publicly traded companies by the first half of 2028. One company will focus on healthcare solutions, including Aetna and CVS Caremark, while the other will be a retail pharmacy company with ...
